**Supplemental Digital Content 2 – Table 2**. Validation of polymorphisms predicting for the thymidine analogue mutation (TAM) 1 pathway. Sequences were obtained from the Stanford database Genotype-Treatment Correlations tool consisting of one genotype performed before treatment exposure and one obtained after any exposure to zidovudine and/ or stavudine.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | TAM 1 (n=21 ) | no TAM 1 (n=15) | Sensitivity | Specificity | % Correctly classified | AUC |
| K43E  | 0 | 0 | - | - | - | - |
| V60I | 1 (6.7%) | 4 (19%) | 26.7% | 95.2% | 66.7% | 0.61 |
| S68G | 1 (6.7%) | 0 | - | - | - | - |
| S162C | 3 (20%) | 2 (9.5%) | 13.3% | 85.7% | 55.6% | 0.50 |
| T165I | 1 (6.7%) | 1 (4.8%) | 7.0% | 95.2% | 58.3% | 0.51 |
| I202V | 1 (6.7%) | 0 | - | - | - | - |
| R211K | 7 (46.7%) | 2 (9.5%) | 13.0% | 66.7% | 44.4% | 0.40 |
| F214L | 1 (6.7%) | 3 (14.3%) | 20.0% | 95.2% | 63.9% | 0.58 |

Abbreviation: Area, area under ROC curve